Understanding the Compounding Pharmacy Restrictions
Recent FDA actions have restricted compounding pharmacies from producing certain peptides for clinical use. This guide explains what happened, what it means for researchers, and how the research peptide market is different.
What Changed?
The FDA determined that certain peptides, including BPC-157 and several others, do not meet the criteria for compounding pharmacy production under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. These peptides were removed from the compounding formulary.
What It Does NOT Affect
The compounding restrictions do NOT apply to research-grade peptides sold for laboratory and research use. Research peptides like BPC-157, TB-500, and others remain available through research chemical suppliers for legitimate research purposes.
Why the Distinction Matters
Compounding pharmacies produce products for individual patient use under a physician’s prescription. Research chemical suppliers provide compounds for laboratory investigation, academic research, and educational purposes. These are fundamentally different regulatory categories.
Impact on Research
The compounding restrictions have actually increased demand for research-grade peptides from quality suppliers. Researchers continue to study these compounds in preclinical settings, contributing to the growing scientific literature.
Quality Assurance
More than ever, research peptide quality matters. Look for suppliers with third-party COAs, HPLC purity verification, and mass spectrometry confirmation. Proxiva Labs maintains 99%+ purity standards across our complete catalog.
For research and educational purposes only.
Related Articles
All products are sold strictly for research purposes only. Not for human consumption.